October 10, 2024

SGLT2 Inhibitor Use Linked to Lower Parkinson Disease Risk in T2D – Renal and Urology News

October 10, 2024

Positive Phase 3 Results for First-in-Class Parkinson’s Med – Medscape

October 10, 2024

Pimavanserin a Better Option for Parkinson’s Psychosis? – Medscape

October 10, 2024

New drug molecule could lead to new treatments for Parkinson’s disease in younger patients – Health e-News

October 10, 2024

Positive Phase 3 Results for First-in-Class Parkinson’s Med

An experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson’s significantly reduce disease burden in two phase 3 trials.